HARTOUNIAN HARTOUN 4

What Happened

• Director Hartoun Hartounian was granted a derivative award on 2026-02-26: options to purchase 225,000 shares of BrainStorm Cell Therapeutics (BCLI) at an exercise price of $0.70 per share (aggregate exercise cost $157,500). This is a grant of stock options under the company’s 2014 Stock Incentive Plan, not an open-market purchase or sale.

Key Details

• Transaction date and terms: 02/26/2026 — 225,000 options @ $0.70 per share (aggregate $157,500).
• Vesting: 50% vests on the grant date; the remaining 50% vests on the six‑month anniversary, subject to continued service.
• Instrument: Options (derivative) granted under the Issuer’s 2014 Stock Incentive Plan.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Form filed 2026-05-20, approximately 83 days after the transaction date (appears late), which delays public transparency though it does not itself indicate trading intent.

Context

• These are option grants (not exercised); they give the holder the right to buy shares at $0.70 in the future if vested and exercised. The award’s immediate economic value depends on BrainStorm’s market price relative to the $0.70 strike and whether/when options are exercised or sold.